Skip to content

Study · Not a test of the peptide alone · 2026

5 results

Cost-Effectiveness of Pharmacologic Treatments in Adults With Overweight or Obesity: A Systematic Review for the American College of Physicians.

Jenniskens K, Huis In 't Veld LF, Lokerse ME, Idema DL, Kusters MPT, van der Braak K, Spijker R, Vernooij RWM, Oerbekke MS, Hooft L, Damen JAA

Annals of internal medicine16 Jun 2026Cited by 3 (Europe PMC)

PMID42296505 (opens in a new tab)DOI10.7326/annals-24-03766 (opens in a new tab)PepBankPUB-42296505
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01Computer modelNot a test of Liraglutide aloneIn silicoOther

    In model-based U.S. evaluations of adults with overweight or obesity, liraglutide had low economic value versus lifestyle modification.

    In plain wordsFor U.S. adults with overweight or obesity, liraglutide had low modeled economic value versus lifestyle intervention.

    Peptide
    Liraglutide
    Outcome
    Not applicableCost-effectiveness value
    Study

    n: not applicable

    model-based cost-effectiveness evaluations
    Comparator
    Lifestyle modification
    Outcome group
    Cost-effectiveness · Pharmacology

    Source sentences

    Summary
    In the 6 studies with moderate certainty, liraglutide had low value and phentermine-topiramate and tirzepatide had high value when each was compared with lifestyle modification.
    5 context sentences
    Summary · context
    MEDLINE, Embase, and economic databases, searched on 13 October 2025.
    Summary · context
    Non-industry-sponsored U.S. trial-based and model-based cost-effectiveness evaluations of pharmacologic treatments in adults with overweight or obesity.
    Summary · context
    All studies were model-based.
    Summary · context
    value was assessed using incremental cost-effectiveness ratios (ICERs), with thresholds for high value (<$100 000 per quality-adjusted life-year [QALY], or dominant)
    Summary · context
    low value (>$200 000 per QALY)

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02Computer modelNot a test of Tirzepatide aloneIn silicoOther

    In model-based U.S. evaluations of adults with overweight or obesity, tirzepatide had high economic value versus lifestyle modification.

    In plain wordsFor U.S. adults with overweight or obesity, tirzepatide had high modeled economic value versus lifestyle intervention.

    Peptide
    Tirzepatide
    Outcome
    Not applicableCost-effectiveness value
    Study

    n: not applicable

    model-based cost-effectiveness evaluations
    Comparator
    Lifestyle modification
    Outcome group
    Cost-effectiveness · Pharmacology

    Source sentences

    Summary
    In the 6 studies with moderate certainty, liraglutide had low value and phentermine-topiramate and tirzepatide had high value when each was compared with lifestyle modification.
    4 context sentences
    Summary · context
    MEDLINE, Embase, and economic databases, searched on 13 October 2025.
    Summary · context
    Non-industry-sponsored U.S. trial-based and model-based cost-effectiveness evaluations of pharmacologic treatments in adults with overweight or obesity.
    Summary · context
    All studies were model-based.
    Summary · context
    value was assessed using incremental cost-effectiveness ratios (ICERs), with thresholds for high value (<$100 000 per quality-adjusted life-year [QALY], or dominant)

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  3. 03Computer modelNot a test of Semaglutide aloneIn silicoOther

    In model-based U.S. evaluations of adults with overweight or obesity, semaglutide had low economic value versus naltrexone-bupropion.

    In plain wordsFor U.S. adults with overweight or obesity, semaglutide had low modeled economic value versus naltrexone-bupropion.

    Peptide
    Semaglutide
    Outcome
    Not applicableCost-effectiveness value
    Study

    n: not applicable

    model-based cost-effectiveness evaluations
    Comparator
    Naltrexone-bupropion
    Outcome group
    Cost-effectiveness · Pharmacology

    Source sentences

    Summary
    Semaglutide had low value compared with naltrexone-bupropion and phentermine-topiramate and high value compared with liraglutide.
    5 context sentences
    Summary · context
    MEDLINE, Embase, and economic databases, searched on 13 October 2025.
    Summary · context
    Non-industry-sponsored U.S. trial-based and model-based cost-effectiveness evaluations of pharmacologic treatments in adults with overweight or obesity.
    Summary · context
    All studies were model-based.
    Summary · context
    value was assessed using incremental cost-effectiveness ratios (ICERs), with thresholds for high value (<$100 000 per quality-adjusted life-year [QALY], or dominant)
    Summary · context
    low value (>$200 000 per QALY)

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 04Computer modelNot a test of Semaglutide aloneIn silicoOther

    In model-based U.S. evaluations of adults with overweight or obesity, semaglutide had low economic value versus phentermine-topiramate.

    In plain wordsFor U.S. adults with overweight or obesity, semaglutide had low modeled economic value versus phentermine-topiramate.

    Peptide
    Semaglutide
    Outcome
    Not applicableCost-effectiveness value
    Study

    n: not applicable

    model-based cost-effectiveness evaluations
    Comparator
    Phentermine-topiramate
    Outcome group
    Cost-effectiveness · Pharmacology

    Source sentences

    Summary
    Semaglutide had low value compared with naltrexone-bupropion and phentermine-topiramate and high value compared with liraglutide.
    5 context sentences
    Summary · context
    MEDLINE, Embase, and economic databases, searched on 13 October 2025.
    Summary · context
    Non-industry-sponsored U.S. trial-based and model-based cost-effectiveness evaluations of pharmacologic treatments in adults with overweight or obesity.
    Summary · context
    All studies were model-based.
    Summary · context
    value was assessed using incremental cost-effectiveness ratios (ICERs), with thresholds for high value (<$100 000 per quality-adjusted life-year [QALY], or dominant)
    Summary · context
    low value (>$200 000 per QALY)

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  5. 05Computer modelNot a test of Semaglutide aloneIn silicoOther

    In model-based U.S. evaluations of adults with overweight or obesity, semaglutide had high economic value versus liraglutide.

    In plain wordsFor U.S. adults with overweight or obesity, semaglutide had high modeled economic value versus liraglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableCost-effectiveness value
    Study

    n: not applicable

    model-based cost-effectiveness evaluations
    Comparator
    Liraglutide
    Outcome group
    Cost-effectiveness · Pharmacology

    Source sentences

    Summary
    Semaglutide had low value compared with naltrexone-bupropion and phentermine-topiramate and high value compared with liraglutide.
    4 context sentences
    Summary · context
    MEDLINE, Embase, and economic databases, searched on 13 October 2025.
    Summary · context
    Non-industry-sponsored U.S. trial-based and model-based cost-effectiveness evaluations of pharmacologic treatments in adults with overweight or obesity.
    Summary · context
    All studies were model-based.
    Summary · context
    value was assessed using incremental cost-effectiveness ratios (ICERs), with thresholds for high value (<$100 000 per quality-adjusted life-year [QALY], or dominant)

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Versions 2 to 3

    9 Oct 2026, 03:07 UTC

    The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.